Navigation Links
Double Helix Strengthens its Strategic Pricing and Reimbursement Practice with Hire of Caryn Zieses
Date:7/20/2009

NEW YORK, July 20 /PRNewswire/ -- Double Helix Consulting US, a division of London-based Double Helix Development group, today announced the appointment of Caryn Zieses to the position of Senior Consultant. Zieses joins a multidisciplinary team of highly experienced strategic pricing, reimbursement and market access consultants with extensive experience across the healthcare industry, which provides product commercialization services to firms in the pharmaceutical, biotechnology and medical device industries. DHC US provides services spanning the product lifecycle, including the following:

  • Product value message development and testing
  • Commercial assessment
  • Development program and clinical trial planning
  • Managed markets strategy
  • Pharmacoeconomic evaluation and health technology assessment
  • Payer and provider insight evaluation and influence planning
  • Pricing and reimbursement strategy, negotiation simulation, and training

Drew Baker, President of Double Helix Consulting US, commented, "Caryn complements our international market access, pricing and reimbursement capabilities through her vast experience in planning and implementing product development and launch strategies for the US market. Her intimate knowledge of managed care market structure, formulary management, contracting strategies, and marketing communications strengthens Double Helix's ability to meet our clients' commercial objectives in the increasingly cost-conscious and value-driven US market."

Chief Executive Officer of Double Helix Development Group, Dr. Wayne Phillips, added, "Double Helix Consulting offers a premier set of services to assist our clients in optimizing product commercialization by enhancing market access through a truly global team of professionals with deep experience from both the client and
'/>"/>

SOURCE Double Helix Consulting US
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Honeywell to Help B. Braun Healthcare Company Double Manufacturing Capacity of Life-Critical Products
2. Double Helix Appoints Ann Stuchiner Vice President of US Consulting Division
3. Nanoparticles double their chances of getting into sticky situations
4. Carbon nanotube avalanche process nearly doubles current
5. SleepQuest Compliance Again Doubles Industry Average
6. London-Based Double Helix Consulting Launches US Division for Strategic Pricing, Reimbursement and Market Access Solutions
7. Rising H9N2 Influenza Replikin Count Has Doubled That of H5N1
8. YM BIOSCIENCES RECEIVES CLEARANCE TO INITIATE RANDOMIZED DOUBLE-BLIND CLINICAL TRIALS OF NIMOTUZUMAB IN LUNG CANCER AND BRAIN METASTASES FROM LUNG CANCER
9. Method sorts out double-walled carbon nanotube problem
10. Premier Research Achieves Double-Digit Growth in Functional Sourcing for the Third Straight Year
11. US Neuropathic Pain Market Value Doubles to $5 Billion by 2018

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2009)...RK, Nov. 30 The Michael... today announced $1.5 million in total awards to s...isease-modifying therapies for Parkinson,s disease...hes to Drug Discovery for Parkinson,s Disease pro...on, plc (NYSE: ELN ), a neuroscience-based biote...
(Date:11/30/2009)...STERDAM, November 30 Biopharmaceut...e first patients have been enrolled in its,multina...The study is,designed to show reduction in transpl...ng an allogeneic stem cell transplantation with a ... patients eligible for an allogeneic,stem cell tra...
(Date:11/30/2009)...LLE, Md., Nov. 30 Novava...mpleted enrollment in the Phase II clinical study ...ommended strains) VLP vaccine candidate in healthy...This randomized, double-blind, active-controlled s...unogenicity of two different doses (15 mcg and 60 ...
(Date:11/30/2009)...EATTLE, Nov. 30 Cell The...nced today that its new class of platinum-based an...rated a stronger anti-tumor potency and activity c...ounds as well as the ability to overcome cisplatin...e presented in a paper titled "Novel Bis-platinum ...
Breaking Biology Technology:The Michael J. Fox Foundation Announces $1.5 Million in Funding to Advance Development of Drug Targets for Disease-Modifying Parkinson's Disease Treatments 2The Michael J. Fox Foundation Announces $1.5 Million in Funding to Advance Development of Drug Targets for Disease-Modifying Parkinson's Disease Treatments 3Kiadis Pharma Announces Enrollment of First Patients in a Multinational Registration Study for ATIR(TM) 2NOVAVAX Completes Enrollment in Phase IIa Study of Seasonal Influenza Vaccine in Older Adults 2NOVAVAX Completes Enrollment in Phase IIa Study of Seasonal Influenza Vaccine in Older Adults 3NOVAVAX Completes Enrollment in Phase IIa Study of Seasonal Influenza Vaccine in Older Adults 4New Class of Platinum-Based Anti-Tumor Drugs, Bisplatinates, Demonstrates Potent Anti-Tumor Activity and Ability to Overcome Resistance to Currently Available Platinum-Based Agents 2New Class of Platinum-Based Anti-Tumor Drugs, Bisplatinates, Demonstrates Potent Anti-Tumor Activity and Ability to Overcome Resistance to Currently Available Platinum-Based Agents 3
...aGen to receive approximately $45 million in cash,...ne payments - - Provides updated financ...o be hosted today at 9:00 a.m. EDT -, BRANFORD, C... ), a clinical-stage biopharmaceutical company, an...linostat, a Phase I/II histone,deacetylase inhibit...
...LLE, Calif., April 21 Ortho Evra is an adhesive,t...release 150 mcg of,norelgestromin and 20 mcg of et... It is replaced once a week for three weeks, and n... was approved by the FDA in November,2001, and ove...pproval.,Ortho Evra continues to be marketed aggre...
... Million Net Revenues, $0.03 Net Loss Per Share, ...logies, Inc. (Nasdaq: VNUS ), a leading provider ...tment of venous disease, today announced its,finan... 2008., Net revenues for the first quarter of 200....6 million for the first quarter of 2007. As,expec...
Other Biology Technology:CuraGen Sells Ownership of Belinostat to TopoTarget A/S 2CuraGen Sells Ownership of Belinostat to TopoTarget A/S 3CuraGen Sells Ownership of Belinostat to TopoTarget A/S 4CuraGen Sells Ownership of Belinostat to TopoTarget A/S 5Ortho Evra Patch Makers Settling Cases 2VNUS Medical Technologies Reports First-Quarter 2008 Results: 21% growth in Net Revenues and 51% Growth in Unit Sales 2VNUS Medical Technologies Reports First-Quarter 2008 Results: 21% growth in Net Revenues and 51% Growth in Unit Sales 3VNUS Medical Technologies Reports First-Quarter 2008 Results: 21% growth in Net Revenues and 51% Growth in Unit Sales 4VNUS Medical Technologies Reports First-Quarter 2008 Results: 21% growth in Net Revenues and 51% Growth in Unit Sales 5VNUS Medical Technologies Reports First-Quarter 2008 Results: 21% growth in Net Revenues and 51% Growth in Unit Sales 6VNUS Medical Technologies Reports First-Quarter 2008 Results: 21% growth in Net Revenues and 51% Growth in Unit Sales 7
(Date:11/30/2009)..., New Orleans, LA Researchers from LSU Health Sc... Eunice Kennedy Shriver National Institute of Chil...hool of Public Health, Brigham and Women,s Hospita...first time that drinking more than 5 servings of s...ears to significantly elevate the risk of developi...
(Date:11/30/2009)..., Two so-called invasion proteins are crucial for...surface of human cells, which stimulates the host ...ptor molecules exert a different function, for exa...ng. The group,s results have now been published in...iology ". , Spoiled meat is one of the sources f...
(Date:11/30/2009)..., If you ever thought the stress of seeing your e...g youbad news: a new research report in the Decemb...iology ( http://www.jleukbio.org ) shows that you...m the same study might lead to entirely new treatm..., arthritis, and eczema under control. That,s beca...
Breaking Biology News(10 mins):Sugary cola drinks linked for first time to higher risk of gestational diabetes 2Sugary cola drinks linked for first time to higher risk of gestational diabetes 3It takes 2 to infect 2Seeing family for the holidays? Scientists discover how the stress might kill you 2UCR scientists manipulate ripples in graphene enabling strain based graphene electronics 13195 1UCR scientists manipulate ripples in graphene enabling strain based graphene electronics 13195 2UCR scientists manipulate ripples in graphene enabling strain based graphene electronics 13195 3Surgery remans an option for advanced lung cancer 52719 1Surgery remans an option for advanced lung cancer 52719 2Common allergy drug reduces obesity and diabetes in mice 9359 1Common allergy drug reduces obesity and diabetes in mice 9359 2Common allergy drug reduces obesity and diabetes in mice 9359 3Common allergy drug reduces obesity and diabetes in mice 9359 4
...rcent of women rely on their healthcare providers ...ercent said their doctor has talked to them about ...avirus (HPV) - according to a new survey released ...onals (ARHP). HPV is extremely common, affecting a...n their lifetime, in some cases staying dormant un...
...r manipulating macromolecules has been developed b...ana-Champaign. The technique uses double-stranded ...In previous DNA nanotechnology efforts, duplex DNA...ometrical objects in three dimensions. Instead of ...rchers are using DNA to control the folding and re...
...r manipulating macromolecules has been developed b...ana-Champaign. The technique uses double-stranded ...In previous DNA nanotechnology efforts, duplex DNA...ometrical objects in three dimensions. Instead of ...rchers are using DNA to control the folding and re...
Other Biology News:Survey reveals women and doctors aren't talking about HPV 2Survey reveals women and doctors aren't talking about HPV 3Health costs soar as 60 million Americans classed as obese 2UN successfully tests 'green' pesticide against locusts 2
Goat Anti-Human SCP3 / SYCP3 Affinity Purified Polyclonal Antibody, Unconjugated from R&D Systems
Rabbit Anti-Human ADH5 Polyclonal Antibody, Unconjugated from Proteintech Group, Inc.
Mouse Anti-Human Rad1 Monoclonal Antibody, Unconjugated, Clone 33 from R&D Systems
Cytological Nuclear Counterstain Kit - DAPI/SYTOX Green/PI - 300 slides from Molecular Probes (Invitrogen)
Biology Products: